OXFORD — A recent study led by Saioa Gomez-Zorita published in the Journal of Agricultural and Food Chemistry has demonstrated the weight loss effects of pterostilbene in rats fed an obesogenic diet. The study confirms the results of a 2012 human clinical trial on the effect of pterostilbene on weight loss conducted by ChromaDex, an innovative natural products company that manufactures a proprietary pterostilbene ingredient, pTeroPure.
As outlined in an Oct. 28 press release, researchers involved with the newly published study, conducted by The University of Basque Country’s (UDV/EHU) nutrition and obesity group in collaboration with the United States Department of Agriculture (USDA), observed in animal models that the administration of pterostilbene “reduces the build-up of body fat, which could reduce the risk of developing other diseases like diabetes.”
In 2012, Irvine, Calif.-based ChromaDex, which provides proprietary ingredients and science-based solutions to the dietary supplement, food and beverage, animal health, cosmetic and pharmaceutical industries, conducted human clinical trials that also demonstrated the effects of pterostilbene on weight loss.
The new data from the Gomez-Zorita animal study is fully consistent with results achieved by ChromaDex in the Phase 2/3 clinical study of its pTeroPure pterostilbene. The study demonstrated that participants taking pTeroPure® at 100 milligram per day lost 3.04 pounds at confidence interval of 94.45 percent (p=0.055). Although statistical significance is based at a 95 percent confidence interval, the data trended toward significance. The study also showed statistically significant results for pterostilbene’s ability to lower blood pressure without any serious adverse side effects.
ChromaDex’s patented pterostilbene – branded as pTeroPure — was named the 2010 North American Most Promising Ingredient of the Year by the independent research company Frost & Sullivan. ChromaDex launched pTeroPure® in 2010 and today, more than 40 consumer products containing pTeroPure® are available in the marketplace.
In 2010, ChromaDex announced an exclusive worldwide license for all patent rights of pterostilbene with the University of Mississippi and the USDA Agricultural Research Service. In April 2014, a collaboration formed by the University of Mississippi’s Division of Technology Management, the USDA Agricultural Research Service’s Natural Products Utilization Research Unit and ChromaDex won a Federal Laboratory Consortium 2014 Excellence in Technology Transfer Award for their work developing pterostilbene.
Commenting on the recent study, Frank Jaksch, co-founder and CEO of ChromaDex stated: “This recently published study further confirms there is a connection between pterostilbene and weight loss. With regard to the pterostilbene human study that we conducted in 2012, we were surprised with the significant trend in weight loss, considering it was only an eight-week study. Given the challenges of finding effective, science-backed weight loss ingredients, our pTeroPure pterostilbene provides the market with an excellent solution.”
BEFORE YOU GO…
… we’d like to ask for your support. More people are reading the Mississippi Business Journal than ever before, but advertising revenues for all conventional media are falling fast. Unlike many, we do not use a pay wall, because we want to continue providing Mississippi’s most comprehensive business news each and every day. But that takes time, money and hard work. We do it because it is important to us … and equally important to you, if you value the flow of trustworthy news and information which have always kept America strong and free for more than 200 years.
If those who read our content will help fund it, we can continue to bring you the very best in news and information. Please consider joining us as a valued member, or if you prefer, make a one-time contribution.Click for more info